Tetra Pharm Technologies introduces pain relieving drug in the United Kingdom
COPENHAGEN, Denmark, March 19, 2024 /PRNewswire/ -- Following last year's successful launch of XATEPA® in Germany, the cannabinoid-based product will now become available to patients in the United Kingdom during Q2 2024.
- The Danish biopharmaceutical company, Tetra Pharm Technologies, is proud to announce the launch of its pain-relieving prescription drug, XATEPA®, in the United Kingdom.
- XATEPA® is a carefully formulated drug designed to provide effective relief from chronic pain as well as discomfort arising from MS spasms and nausea.
- For the distribution of XATEPA® in the United Kingdom, Tetra Pharm Technologies has entered a strategic agreement with 4C LABS Ltd. who cooperate with a wide network of clinics, doctors, and patient organizations.
- "4C LABS are excited to be the exclusive distributors in the United Kingdom for the suite of Tetra Pharm Technologies' cannabinoid-based prescription drugs.